Home | FCA & regulatory news | British English edition
Trade Hub UK

Independent coverage of UK markets, FCA policy and institutional trading
AD CME Group Education AD Bank of England Statistics AD Investing.com Markets AD LSEG Data
City & Markets

Aptevo Therapeutics Inc. Reports 21% of Frontline AML Patients in Mipletamig Combination Study Advanced to Stem Cell Transplant

Trade Hub UK briefing (2026-10-26): Aptevo Therapeutics Inc. Reports 21% of Frontline AML Patients in Mipletamig Combination Study Advanced to Stem Cell Transplant Aptevo Therapeutics Inc.… Primary source: original at Nasdaq (nasdaq.com).

By Nasdaq

Aptevo Therapeutics Inc. Reports 21% of Frontline AML Patients in Mipletamig Combination Study Advanced to Stem Cell Transplant

Aptevo Therapeutics Inc. announced that ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine. Specifically, ten of 47 (21%) evaluable fron

Read at source

Read also
  1. ‘We don’t have inflation’? Five charts show the US economic reality of Trump’s second term so far
  2. Is getting a wedding band from Quince a bad idea? It’s a third of the price of a local jeweler.
  3. Trump DOJ unlawfully fired Epstein prosecutor Maurene Comey, judge rules
  4. Donegal Group Consensus Price Target Increased 20.45% to $22.44
  5. Yue Yuen Industrial Consensus Price Target Decreased 12.41% to $8.41

Source: Nasdaq